BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L, Moratti R, Bonino C, Montecucco C. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010;37:2064-70. [PMID: 20634241 DOI: 10.3899/jrheum.090997] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Marra AM, Bossone E, Salzano A, D’assante R, Monaco F, Ferrara F, Arcopinto M, Vriz O, Suzuki T, Cittadini A. Biomarkers in Pulmonary Hypertension. Heart Failure Clinics 2018;14:393-402. [DOI: 10.1016/j.hfc.2018.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zhang Y, Qin D, Qin L, Yang X, Luo Q, Wang H. Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis. Joint Bone Spine 2021;89:105287. [PMID: 34601113 DOI: 10.1016/j.jbspin.2021.105287] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Heresi GA. Clinical perspective: biomarkers in pulmonary arterial hypertension. Int J Clin Pract Suppl 2011;:5-7. [PMID: 21176009 DOI: 10.1111/j.1742-1241.2010.02598.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moon JY, Leitao Filho FS, Shahangian K, Takiguchi H, Sin DD. Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD). Expert Rev Proteomics 2018;15:923-35. [PMID: 30362838 DOI: 10.1080/14789450.2018.1539670] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Humbert M, Singh M, Furst DE, Khanna D, Seibold JR. Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology (Oxford) 2017;56:v33-7. [PMID: 28992168 DOI: 10.1093/rheumatology/kex197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol 2011;23:536-44. [PMID: 21934501 DOI: 10.1097/BOR.0b013e32834ba6a7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
7 Tamura Y, Ono T, Kuwana M, Inoue K, Takei M, Yamamoto T, Kawakami T, Fujita J, Kataoka M, Kimura K, Sano M, Daida H, Satoh T, Fukuda K. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One 2012;7:e45834. [PMID: 23029266 DOI: 10.1371/journal.pone.0045834] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
8 Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, Simms RW, Domsic R, Farber HW, Layfatis R. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2018;20:185. [PMID: 30115106 DOI: 10.1186/s13075-018-1679-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol 2018;45:633-91. [PMID: 29687465 DOI: 10.1111/1346-8138.14162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
10 Rao V, Bowman S. Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis. 2013;5:234-249. [PMID: 23904866 DOI: 10.1177/1759720x13480280] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hasegawa M. Biomarkers in systemic sclerosis: Their potential to predict clinical courses. J Dermatol 2016;43:29-38. [PMID: 26782004 DOI: 10.1111/1346-8138.13156] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
12 Chung L, Chen H, Khanna D, Steen VD. Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire. Arthritis Care Res 2013;65:454-63. [DOI: 10.1002/acr.21827] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
13 Gajecki D, Gawrys J, Szahidewicz-Krupska E, Doroszko A. Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targets-From Bench to Bed Site. Oxid Med Cell Longev 2020;2020:7265487. [PMID: 32566097 DOI: 10.1155/2020/7265487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2013;15:R193. [PMID: 24246100 DOI: 10.1186/ar4383] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
15 Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas G. B-type natriuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant? Autoimmun Rev 2012;11:837-43. [PMID: 22401930 DOI: 10.1016/j.autrev.2012.02.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
16 Kan C, Cao J, Hou J, Jing X, Zhu Y, Zhang J, Guo Y, Chen X. Correlation of miR-21 and BNP with pregnancy-induced hypertension complicated with heart failure and the diagnostic value. Exp Ther Med 2019;17:3129-35. [PMID: 30936985 DOI: 10.3892/etm.2019.7286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Desai CS, Lee DC, Shah SJ. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011;23:545-54. [PMID: 21897256 DOI: 10.1097/BOR.0b013e32834b8975] [Cited by in Crossref: 57] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
18 Castelino FV, Varga J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol 2013;9:1077-90. [PMID: 24168414 DOI: 10.1586/1744666X.2013.848792] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
19 Bruni C, De Luca G, Lazzaroni MG, Zanatta E, Lepri G, Airò P, Dagna L, Doria A, Matucci-Cerinic M. Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. Eur J Intern Med 2020;78:17-25. [PMID: 32540411 DOI: 10.1016/j.ejim.2020.05.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Castellví I, Simeón CP, Sarmiento M, Casademont J, Corominas H, Fonollosa V. Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. PLoS One 2020;15:e0243651. [PMID: 33301540 DOI: 10.1371/journal.pone.0243651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Romanowska-Próchnicka K, Walczyk M, Olesińska M. Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria. Reumatologia 2016;54:296-305. [PMID: 28115780 DOI: 10.5114/reum.2016.64906] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 . Current world literature. Curr Opin Rheumatol 2011;23:620-5. [PMID: 21960037 DOI: 10.1097/BOR.0b013e32834ccef6] [Reference Citation Analysis]
23 Cavagna L, Codullo V, Ghio S, Scirè CA, Guzzafame E, Scelsi L, Rossi S, Montecucco C, Caporali R. Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients. Medicine (Baltimore) 2016;95:e4827. [PMID: 27684814 DOI: 10.1097/MD.0000000000004827] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
24 Karampitsakos T, Tzouvelekis A, Chrysikos S, Bouros D, Tsangaris I, Fares WH. Pulmonary hypertension in patients with interstitial lung disease. Pulm Pharmacol Ther 2018;50:38-46. [PMID: 29605286 DOI: 10.1016/j.pupt.2018.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
25 Becker MO, Riemekasten G. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol 2016;12:115-35. [PMID: 26558747 DOI: 10.1586/1744666X.2016.1115717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
26 Valenzuela A, Nandagopal S, Steen VD, Chung L. Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Rheum Dis Clin North Am 2015;41:489-506. [PMID: 26210131 DOI: 10.1016/j.rdc.2015.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
27 Bissell LA, Anderson M, Burgess M, Chakravarty K, Coghlan G, Dumitru RB, Graham L, Ong V, Pauling JD, Plein S, Schlosshan D, Woolfson P, Buch MH. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 2017;56:912-21. [PMID: 28160468 DOI: 10.1093/rheumatology/kew488] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 7.6] [Reference Citation Analysis]
28 Naranjo M, Hassoun PM. Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. Diagnostics (Basel) 2021;11:911. [PMID: 34065226 DOI: 10.3390/diagnostics11050911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Odler B, Foris V, Gungl A, Müller V, Hassoun PM, Kwapiszewska G, Olschewski H, Kovacs G. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. Front Physiol 2018;9:587. [PMID: 29971007 DOI: 10.3389/fphys.2018.00587] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
30 Bournia V, Tountas C, Protogerou AD, Panopoulos S, Mavrogeni S, Sfikakis PP. Update on assessment and management of primary cardiac involvement in systemic sclerosis. Journal of Scleroderma and Related Disorders 2018;3:53-65. [DOI: 10.1177/2397198317747441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
31 Xu S, Yang J, Zhang C, Xu S, Zhao F, Liu L, Xie C, Xing X, Zhu Y. Serum cardiac troponin elevation predicts mortality in patients with pulmonary hypertension: A meta-analysis of eight cohort studies. Clin Respir J 2019;13:82-91. [DOI: 10.1111/crj.12991] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Collins S, Storrow AB, Albert NM, Butler J, Ezekowitz J, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander JE, Lanfear DE, Levy PD, Pang PS, Peacock WF, Sawyer DB, Teerlink JR, Lenihan DJ; SAEM/HFSA Acute Heart Failure Working Group. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. J Card Fail 2015;21:27-43. [PMID: 25042620 DOI: 10.1016/j.cardfail.2014.07.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
33 Affandi AJ, Radstake TR, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol 2015;37:475-87. [PMID: 26168983 DOI: 10.1007/s00281-015-0506-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
34 Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med 2020;9:E3388. [PMID: 33105647 DOI: 10.3390/jcm9113388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340-1349. [PMID: 23687283 DOI: 10.1136/annrheumdis-2013-203301] [Cited by in Crossref: 386] [Cited by in F6Publishing: 316] [Article Influence: 42.9] [Reference Citation Analysis]
36 Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics 2017;17:823-33. [DOI: 10.1080/14737159.2017.1356722] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
37 Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013;144:1346-56. [PMID: 24081346 DOI: 10.1378/chest.12-2396] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
38 Thakkar V, Stevens WM, Moore OA, Nikpour M. Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review: Screening algorithms in SSc-PAH. Intern Med J 2013;43:751-60. [DOI: 10.1111/imj.12167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
39 Gladue H, Steen V, Allanore Y, Saggar R, Saggar R, Maranian P, Berrocal VJ, Avouac J, Meune C, Trivedi M, Khanna D. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. J Rheumatol 2013;40:1706-11. [PMID: 23950183 DOI: 10.3899/jrheum.130400] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
40 Ojima S, Kubozono T, Saihara K, Miyauchi T, Kawasoe S, Kubota K, Shigemizu S, Ohtsubo H, Miyata M, Ohishi M. Significant Clinical Indexes of Exercise-Induced Pulmonary Hypertension in Patients With Connective Tissue Disease. Circ Rep 2019;1:610-6. [PMID: 33693107 DOI: 10.1253/circrep.CR-19-0087] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Gladue H, Altorok N, Townsend W, McLaughlin V, Khanna D. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 2014;43:536-41. [PMID: 24012044 DOI: 10.1016/j.semarthrit.2013.08.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
42 Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S, Provencher S. Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ 2013;3:74-81. [PMID: 23662177 DOI: 10.4103/2045-8932.109917] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
43 Minai OA. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. Ann Thorac Med 2014;9:S92-7. [PMID: 25077003 DOI: 10.4103/1817-1737.134047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 Collins SP, Storrow AB, Levy PD, Albert N, Butler J, Ezekowitz JA, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander JE, Lanfear DE, Pang PS, Peacock WF, Sawyer DB, Teerlink JR, Lenihan DJ. Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. Acad Emerg Med 2015;22:94-112. [PMID: 25423908 DOI: 10.1111/acem.12538] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
45 Ivanovic BA, Tadic MV, Zlatanovic MM, Damjanov NN, Ostojić PM, Bonaci-Nikolic BN. Which factors impact myocardial function in systemic sclerosis? Echocardiography 2012;29:307-17. [PMID: 22066854 DOI: 10.1111/j.1540-8175.2011.01560.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]